Craske, Michelle G.
Stein, Murray B.
Eley, Thalia C.
Milad, Mohammed R.
Holmes, Andrew
Rapee, Ronald M.
Wittchen, Hans-Ulrich
Article History
First Online: 4 May 2017
Competing interests
: M.B.S. has received consulting fees in the past 3 years from Actelion Pharmaceuticals, Janssen, Neurocrine Biosciences, and Pfizer, and stock options from Oxeia Biopharmaceuticals and Resilience Therapeutics. M.B.S. also receives editorial honoraria from the journal <i>Biological Psychiatry</i>, and in his role of Co-Editor-in-Chief for UpToDate in Psychiatry. All other authors declare no competing interests.